Datasheet

Version: 2.0.0 Revision date: 28 May 2025



Dacetuzumab

Catalogue No.:abx831121

Dacetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.

Target: CD40

Clonality: Monoclonal

Reactivity: Human

Expression: Recombinant

Tested Applications: ELISA, WB

Host: Human

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Isotype: IgG₁ Kappa

Form: Liquid

Purity: > 95%

Purification: Purified from cell culture supernatants by Protein A/G chromatography.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

Buffer: 0.01 M PBS. pH 7.4.

CAS Number: 880486-59-9

Concentration: Batch-dependent, typically between 0.5-2.0 mg/ml.

Datasheet

Version: 2.0.0 Revision date: 28 May 2025



Note:

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.



2 of 2

Website: www.abbexa.com · Email: info@abbexa.com